Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

CD71+ Population Enriched by HPV-E6 Protein Promotes Cancer Aggressiveness and Radioresistance in Cervical Cancer Cells.

Leung TH, Tang HW, Siu MK, Chan DW, Chan KK, Cheung AN, Ngan HY.

Mol Cancer Res. 2019 Sep;17(9):1867-1880. doi: 10.1158/1541-7786.MCR-19-0068. Epub 2019 Jun 24.

PMID:
31235657
2.

Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades.

Siu MKY, Jiang YX, Wang JJ, Leung THY, Han CY, Tsang BK, Cheung ANY, Ngan HYS, Chan KKL.

Cancers (Basel). 2019 Jun 12;11(6). pii: E813. doi: 10.3390/cancers11060813.

3.

Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, Casey O, Chen WY, Fang L, Hynes P, Hsieh YY, Liu YN, Huang J, Kelly K.

Oncotarget. 2018 Aug 17;9(64):32403. doi: 10.18632/oncotarget.26020. eCollection 2018 Aug 17.

4.

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer.

Chan KKL, Siu MKY, Jiang YX, Wang JJ, Leung THY, Ngan HYS.

Cancer Cell Int. 2018 May 1;18:65. doi: 10.1186/s12935-018-0559-2. eCollection 2018.

5.

Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.

Leung TH, Tang HW, Siu MK, Chan DW, Chan KK, Cheung AN, Ngan HY.

J Pathol. 2018 Feb;244(2):151-163. doi: 10.1002/path.4991. Epub 2017 Dec 19.

PMID:
28944962
6.

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.

Chan KKL, Siu MKY, Jiang YX, Wang JJ, Wang Y, Leung THY, Liu SS, Cheung ANY, Ngan HYS.

BMC Cancer. 2017 Aug 31;17(1):606. doi: 10.1186/s12885-017-3601-1.

7.

Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.

Chen WY, Tsai YC, Siu MK, Yeh HL, Chen CL, Yin JJ, Huang J, Liu YN.

Oncogene. 2017 Nov 9;36(45):6213-6224. doi: 10.1038/onc.2017.226. Epub 2017 Jul 10.

PMID:
28692046
8.

TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.

Siu MK, Chen WY, Tsai HY, Chen HY, Yin JJ, Chen CL, Tsai YC, Liu YN.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):172-178. doi: 10.1038/pcan.2017.2. Epub 2017 Feb 21.

PMID:
28220803
9.

KLF4 functions as an activator of the androgen receptor through reciprocal feedback.

Siu MK, Suau F, Chen WY, Tsai YC, Tsai HY, Yeh HL, Liu YN.

Oncogenesis. 2016 Dec 19;5(12):e282. doi: 10.1038/oncsis.2016.79.

10.

Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy.

Zhang Z, Zhang G, Sun Y, Szeto SS, Law HC, Quan Q, Li G, Yu P, Sho E, Siu MK, Lee SM, Chu IK, Wang Y.

Sci Rep. 2016 Nov 14;6:37148. doi: 10.1038/srep37148.

11.

Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6.

Tsai YC, Chen WY, Siu MK, Tsai HY, Yin JJ, Huang J, Liu YN.

Cancer Lett. 2017 Jan 1;384:1-8. doi: 10.1016/j.canlet.2016.10.014. Epub 2016 Oct 13.

PMID:
27746161
12.

Androgen receptor regulates SRC expression through microRNA-203.

Siu MK, Chen WY, Tsai HY, Yeh HL, Yin JJ, Liu SY, Liu YN.

Oncotarget. 2016 May 3;7(18):25726-41. doi: 10.18632/oncotarget.8366.

13.

p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation.

Siu MK, Kong DS, Ngai SY, Chan HY, Jiang L, Wong ES, Liu SS, Chan KK, Ngan HY, Cheung AN.

PLoS One. 2015 Jul 28;10(7):e0133467. doi: 10.1371/journal.pone.0133467. eCollection 2015.

14.

FBI-1 Is Overexpressed in Gestational Trophoblastic Disease and Promotes Tumor Growth and Cell Aggressiveness of Choriocarcinoma via PI3K/Akt Signaling.

Mak VC, Wong OG, Siu MK, Wong ES, Ng WY, Wong RW, Chan KK, Ngan HY, Cheung AN.

Am J Pathol. 2015 Jul;185(7):2038-48. doi: 10.1016/j.ajpath.2015.03.011.

PMID:
26093985
15.

Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.

Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F, Chen WY, Liu YN.

Oncogene. 2015 Sep 3;34(36):4767-76. doi: 10.1038/onc.2014.414. Epub 2014 Dec 22.

PMID:
25531317
16.

Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.

Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Gomes AR, Bella L, Khongkow P, Lam EW, Cheung AN.

PLoS One. 2014 Nov 20;9(11):e113478. doi: 10.1371/journal.pone.0113478. eCollection 2014.

17.

Downregulation of the gli transcription factors regulator Kif7 facilitates cell survival and migration of choriocarcinoma cells.

Ho J, Du Y, Wong OG, Siu MK, Chan KK, Cheung AN.

PLoS One. 2014 Sep 29;9(9):e108248. doi: 10.1371/journal.pone.0108248. eCollection 2014.

18.

Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, Casey O, Chen WY, Fang L, Hynes P, Hsieh YY, Liu YN, Huang J, Kelly K.

Oncotarget. 2014 Jun 15;5(11):3770-84. Erratum in: Oncotarget. 2018 Aug 17;9(64):32403.

19.

Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.

Chan KK, Leung TH, Chan DW, Wei N, Lau GT, Liu SS, Siu MK, Ngan HY.

J Endocrinol. 2014 May 12;221(2):325-36. doi: 10.1530/JOE-13-0500. Print 2014 May.

PMID:
24819599
20.
21.

Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation.

Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN.

Carcinogenesis. 2013 Sep;34(9):2170-7. doi: 10.1093/carcin/bgt161. Epub 2013 May 13.

PMID:
23671128
22.

Photochemical route for accessing amorphous metal oxide materials for water oxidation catalysis.

Smith RD, Prévot MS, Fagan RD, Zhang Z, Sedach PA, Siu MK, Trudel S, Berlinguette CP.

Science. 2013 Apr 5;340(6128):60-3. doi: 10.1126/science.1233638. Epub 2013 Mar 28.

23.

The blood-follicle barrier (BFB) in disease and in ovarian function.

Siu MK, Cheng CY.

Adv Exp Med Biol. 2012;763:186-92.

24.

Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome.

Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, Ngan HY, Le XF, Cheung AN.

PLoS One. 2012;7(11):e47201. doi: 10.1371/journal.pone.0047201. Epub 2012 Nov 7.

25.

Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers.

Siu MK, Wong ES, Kong DS, Chan HY, Jiang L, Wong OG, Lam EW, Chan KK, Ngan HY, Le XF, Cheung AN.

Oncogene. 2013 Jul 25;32(30):3500-9. doi: 10.1038/onc.2012.363. Epub 2012 Sep 3.

PMID:
22945654
26.

Dysregulated stemness-related genes in gynecological malignancies.

Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY, Cheung AN.

Histol Histopathol. 2012 Sep;27(9):1121-30. doi: 10.14670/HH-27.1121. Review.

PMID:
22806899
27.

Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival.

Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Chan HY, Cheung AN.

Histopathology. 2011 Dec;59(6):1163-72. doi: 10.1111/j.1365-2559.2011.04045.x.

PMID:
22175896
28.

iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.

Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, Ngan HY, Le XF, Wong ES, Monteiro LJ, Chan HY, Cheung AN.

Clin Cancer Res. 2011 Nov 1;17(21):6924-33. doi: 10.1158/1078-0432.CCR-11-0588. Epub 2011 Sep 16.

29.
30.

Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma.

Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY, Wong OG, Zhang HQ, Cheung AN.

Carcinogenesis. 2011 May;32(5):765-71. doi: 10.1093/carcin/bgr033. Epub 2011 Feb 16. Retraction in: Carcinogenesis. 2016 May;37(5):530.

PMID:
21325635
31.

Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers.

Jiang L, Siu MK, Wong OG, Tam KF, Lam EW, Ngan HY, Le XF, Wong ES, Chan HY, Cheung AN.

Mol Cancer. 2010 Dec 21;9:318. doi: 10.1186/1476-4598-9-318.

32.

Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome.

Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN.

Mod Pathol. 2011 Apr;24(4):522-32. doi: 10.1038/modpathol.2010.216. Epub 2010 Nov 19.

33.

p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Strömblad S, Cheung AN.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18622-7. doi: 10.1073/pnas.0907481107. Epub 2010 Oct 6.

34.

Hypermethylation of SOX2 Promoter in Endometrial Carcinogenesis.

Wong OG, Huo Z, Siu MK, Zhang H, Jiang L, Wong ES, Cheung AN.

Obstet Gynecol Int. 2010;2010. pii: 682504. doi: 10.1155/2010/682504. Epub 2010 Aug 9.

35.

Overexpression of the Parkinson disease protein DJ-1 and its regulator PTEN in gestational trophoblastic disease.

Zhang HJ, Siu MK, Jiang LL, Mak VC, Ngan HY, Cheung AN.

Int J Gynecol Pathol. 2010 Sep;29(5):468-75. doi: 10.1097/PGP.0b013e3181de3068.

PMID:
20736773
36.

p21-Activated kinase-1 promotes aggressive phenotype, cell proliferation, and invasion in gestational trophoblastic disease.

Siu MK, Yeung MC, Zhang H, Kong DS, Ho JW, Ngan HY, Chan DC, Cheung AN.

Am J Pathol. 2010 Jun;176(6):3015-22. doi: 10.2353/ajpath.2010.091263. Epub 2010 Apr 22.

37.

P634A4 and TAp73 immunocytochemistry in liquid-based cervical cytology--potential biomarkers for diagnosis and progress prediction of cervical neoplasia.

Cheung AN, Tsun KL, Ng KM, Szeto E, Siu MK, Wong ES, Ngan HY.

Mod Pathol. 2010 Apr;23(4):559-66. doi: 10.1038/modpathol.2009.198. Epub 2010 Jan 15.

38.

Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion.

Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan HY, Chan QK, Chan DC, Chan KY, Cheung AN.

Int J Cancer. 2010 Jul 1;127(1):21-31. doi: 10.1002/ijc.25005.

39.

Extracellular matrix and its role in spermatogenesis.

Siu MK, Cheng CY.

Adv Exp Med Biol. 2008;636:74-91. doi: 10.1007/978-0-387-09597-4_5. Review.

40.

TrkB as a therapeutic target for ovarian cancer.

Siu MK, Wong OG, Cheung AN.

Expert Opin Ther Targets. 2009 Oct;13(10):1169-78. doi: 10.1517/14728220903196787. Review.

PMID:
19694498
41.

Aberrant activation of hedgehog signaling pathway contributes to endometrial carcinogenesis through beta-catenin.

Liao X, Siu MK, Au CW, Chan QK, Chan HY, Wong ES, Ip PP, Ngan HY, Cheung AN.

Mod Pathol. 2009 Jun;22(6):839-47. doi: 10.1038/modpathol.2009.45. Epub 2009 Mar 27.

42.

Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome.

Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, Chan DC, Chan QK, Cheung AN.

Cancer Lett. 2009 Aug 28;281(2):151-61. doi: 10.1016/j.canlet.2009.02.025.

PMID:
19307055
43.

Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives.

Cheung AN, Zhang HJ, Xue WC, Siu MK.

Future Oncol. 2009 Mar;5(2):217-31. doi: 10.2217/14796694.5.2.217. Review.

PMID:
19284380
44.

P63 expression in gestational trophoblastic disease: correlation with proliferation and apoptotic dynamics.

Zhang HJ, Xue WC, Siu MK, Liao XY, Ngan HY, Cheung AN.

Int J Gynecol Pathol. 2009 Mar;28(2):172-8. doi: 10.1097/PGP.0b013e318189555b.

PMID:
19188816
45.

Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation.

Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY, Cheung AN.

Carcinogenesis. 2009 Jan;30(1):131-40. doi: 10.1093/carcin/bgn230. Epub 2008 Nov 20.

PMID:
19028702
46.

Hypermethylation of SOX2 gene in hydatidiform mole and choriocarcinoma.

Li AS, Siu MK, Zhang H, Wong ES, Chan KY, Ngan HY, Cheung AN.

Reprod Sci. 2008 Sep;15(7):735-44. doi: 10.1177/1933719108322433.

PMID:
18836133
47.

Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome.

Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, Cheung AN.

Am J Pathol. 2008 Oct;173(4):1165-72. doi: 10.2353/ajpath.2008.080288. Epub 2008 Sep 4.

48.

Activated Stat3 expression in gestational trophoblastic disease: correlation with clinicopathological parameters and apoptotic indices.

Chan HY, Siu MK, Zhang HJ, Wong ES, Ngan HY, Chan KY, Cheung AN.

Histopathology. 2008 Aug;53(2):139-46. doi: 10.1111/j.1365-2559.2008.03089.x.

PMID:
18752497
49.

Oct4 is epigenetically regulated by methylation in normal placenta and gestational trophoblastic disease.

Zhang HJ, Siu MK, Wong ES, Wong KY, Li AS, Chan KY, Ngan HY, Cheung AN.

Placenta. 2008 Jun;29(6):549-54. doi: 10.1016/j.placenta.2008.03.003. Epub 2008 Apr 28.

PMID:
18440631
50.

Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.

Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, Li AS, Khoo US, Cheung AN.

Int J Cancer. 2008 Jul 15;123(2):296-302. doi: 10.1002/ijc.23494.

Supplemental Content

Support Center